BR0016986A - Composto anticâncer e método de separação de enantiÈmeros útil para a sìntese do referido composto - Google Patents

Composto anticâncer e método de separação de enantiÈmeros útil para a sìntese do referido composto

Info

Publication number
BR0016986A
BR0016986A BR0016986-2A BR0016986A BR0016986A BR 0016986 A BR0016986 A BR 0016986A BR 0016986 A BR0016986 A BR 0016986A BR 0016986 A BR0016986 A BR 0016986A
Authority
BR
Brazil
Prior art keywords
compound
synthesis
separation method
method useful
enantiomer separation
Prior art date
Application number
BR0016986-2A
Other languages
English (en)
Inventor
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0016986A publication Critical patent/BR0016986A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

"COMPOSTO ANTICâNCER E MéTODO DE SEPARAçãO DE ENANTIÈMEROS úTIL PARA A SìNTESE DO REFERIDO COMPOSTO". A presente invenção refere-se ao composto (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3H-imidazol-4-iI)-metil]-4-(3-cl oro-fenil)-1-ciclopropilmetil-1H-quinolin-2-ona, seus sais e solvatos farmaceuticamente aceitáveis, suas pró-drogas, e ao uso do referido composto para a inibição do crescimento de célula anormal, incluindo câncer, em mamíferos. A invenção também refere-se a métodos úteis na síntese do composto acima mencionado.
BR0016986-2A 2000-01-21 2000-11-29 Composto anticâncer e método de separação de enantiÈmeros útil para a sìntese do referido composto BR0016986A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17771800P 2000-01-21 2000-01-21
PCT/IB2000/001769 WO2001053289A1 (en) 2000-01-21 2000-11-29 Anticancer compound and enantiomer separation method useful for synthesizing said compound

Publications (1)

Publication Number Publication Date
BR0016986A true BR0016986A (pt) 2002-10-08

Family

ID=22649709

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016986-2A BR0016986A (pt) 2000-01-21 2000-11-29 Composto anticâncer e método de separação de enantiÈmeros útil para a sìntese do referido composto

Country Status (17)

Country Link
US (1) US6479513B2 (pt)
EP (1) EP1248782A1 (pt)
JP (2) JP2003520796A (pt)
AR (1) AR029792A1 (pt)
AU (1) AU2001214087A1 (pt)
BR (1) BR0016986A (pt)
CA (1) CA2398353C (pt)
CO (1) CO5271702A1 (pt)
GT (1) GT200100008A (pt)
HN (1) HN2000000266A (pt)
MX (1) MXPA02007153A (pt)
MY (1) MY126069A (pt)
PA (1) PA8508101A1 (pt)
PE (1) PE20011118A1 (pt)
SV (1) SV2002000291A (pt)
TN (1) TNSN01009A1 (pt)
WO (1) WO2001053289A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
ES2328225T3 (es) 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
US7408063B2 (en) 2001-12-19 2008-08-05 Janssen Pharmaceutica, N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
US7241777B2 (en) 2002-03-22 2007-07-10 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
MXPA05006676A (es) * 2002-12-19 2005-08-16 Pfizer Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso.
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
US7524961B2 (en) 2004-05-03 2009-04-28 Janssen Pharmaceutica, N.V. Diastereoselective addition of lithiated N-methylimidazole on sulfinimines
ATE471316T1 (de) * 2004-05-03 2010-07-15 Janssen Pharmaceutica Nv Diastereoselektives syntheseverfahren mit 6-brom- 4-(3-chlorphenyl)-2-methoxychinolin
CA2563807C (en) * 2004-05-03 2012-11-20 Janssen Pharmaceutica N.V. Diastereoselective synthesis process for the preparation of imidazole compounds
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PT1784396E (pt) * 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2009001715A (es) 2006-08-21 2009-02-25 Hoffmann La Roche Terapia tumoral con un anticuerpo anti-vegf.
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
OA11645A (en) 1998-08-27 2004-11-16 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
CN1340051A (zh) * 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.

Also Published As

Publication number Publication date
CA2398353A1 (en) 2001-07-26
CO5271702A1 (es) 2003-04-30
JP2007326868A (ja) 2007-12-20
HN2000000266A (es) 2001-05-21
US20020004514A1 (en) 2002-01-10
JP2003520796A (ja) 2003-07-08
MXPA02007153A (es) 2002-12-13
WO2001053289A1 (en) 2001-07-26
US6479513B2 (en) 2002-11-12
SV2002000291A (es) 2002-07-16
TNSN01009A1 (fr) 2005-11-10
CA2398353C (en) 2007-07-31
EP1248782A1 (en) 2002-10-16
PA8508101A1 (es) 2002-08-26
AU2001214087A1 (en) 2001-07-31
GT200100008A (es) 2001-10-19
PE20011118A1 (es) 2001-11-06
MY126069A (en) 2006-09-29
AR029792A1 (es) 2003-07-16

Similar Documents

Publication Publication Date Title
BR0016986A (pt) Composto anticâncer e método de separação de enantiÈmeros útil para a sìntese do referido composto
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2005082892A3 (en) Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
WO2005009954A3 (en) Method for modulating calcium ion-release-activated calcium ion channels
WO2006053342A3 (en) Integrin antagonists useful as anticancer agents
WO2008001101A3 (en) Pharmaceutical combinations
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2006037024A3 (en) Salts of decitabine
BG106440A (en) Nitrogen-heterocyclic derivatives as nos inhibitors
RS20080272A (en) Pyramidine derivatives for the treatment of abnormal cell growth
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
MXPA02011844A (es) Compuestos con un grupo de sulfonamida, y composiciones farmaceuticas que contienen estos compuestos.
BR9803887A (pt) Macrociclos.
SG156633A1 (en) Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
NO20023139L (no) Liposomer som inneholder en forbindelse i supermettet lösning
AU6584801A (en) Process for the preparation of pharmaceutically acceptable salts of (ss-rs)-s-adenosyl-l-methionine
HK1055741A1 (en) A pyridine-1-oxide derivative, and process for itstransformation into pharmaceutically effective co mpounds
WO2006124865A3 (en) Biaryls derivatives useful as modulators of ion channels
HRP20050603A2 (en) Novel anticonvulsant derivative salts
BRPI0507802A (pt) composto, composição, e, método para tratar inflamação ou um distúrbio metabólico
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.